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Abstract
Cognitive impairment and behavioral changes in amyotrophic lateral sclerosis 
(ALS) are now recognized as part of the disease. Whether it is solely related to 
the extent of TDP- 43 pathology is currently unclear. We aim to evaluate the in-
fluence of age, genetics, neuropathological features, and concomitant patholo-
gies on cognitive impairment in ALS patients. We analyzed a postmortem series 
of 104 ALS patients and retrospectively reviewed clinical and neuropathologi-
cal data. We assessed the burden and extent of concomitant pathologies, the 
role of APOE ε4 and mutations, and correlated these findings with cognitive 
status. We performed a logistic regression model to identify which pathologies 
are related to cognitive impairment. Cognitive decline was recorded in 38.5% of 
the subjects. Neuropathological features of frontotemporal lobar degeneration 
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1 |  INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a neurodegen-
erative disorder characterized by progressive weakness 
and atrophy because of loss of motor neurons. Cognitive 
decline and behavioral impairment have been recently 
recognized as part of the disease (1,2). Approximately 
half of the patients with ALS have cognitive or behav-
ioral impairment and around 10– 20% fulfill clinical 
diagnostic criteria of any of the clinical variants of 
frontotemporal dementia (FTD), mainly behavioral 
variant (bvFTD), but also of primary progressive apha-
sia (PPA) (2– 5). The majority of ALS cases and almost 
half of FTD patients harbor neuronal, and a propor-
tion also glial, inclusions of TAR DNA- binding pro-
tein 43 (TDP- 43) at neuropathological examination. In 
addition, both diseases share genetic alterations such 
as the hexanucleotide expansion in chromosome 9 open 
reading frame 72 (C9orf72) gene, as well as mutations 
in the tank- binding kinase 1 (TBK1), sequestosome- 1 
(SQSTM1), TAR DNA- binding protein (TARDBP), or 
valosin- containing protein (VCP). For these reasons, 
ALS and FTD are now recognized as a disease con-
tinuum (6). FTLD is the pathological substrate under-
lying most FTD cases. The term frontotemporal lobar 
degeneration (FTLD) is used as an umbrella term for 
the different clinical variants (bvFTD, semantic, and 
non- f luent PPA) as well as a neuropathological term 
that refers to neuronal loss and gliosis of the frontal 
and temporal lobes. As a matter of clarity, we refer to 
the neuropathological concept when using the term 
FTLD throughout the text.
On the other hand, concomitant neurodegenera-
tive disease- related proteinopathies are frequent and 
have been primarily associated with age at death (7– 9). 
It remains unclear whether this overlap is coincidental 
or driven by common physiopathological mechanisms 
leading to global protein misfolding and aggregation. 
Genetic factors, especially the presence of apolipopro-
tein E (APOE) ε 4 allele, an extensively studied potential 
genetic risk in Alzheimer’s disease (AD), has been asso-
ciated with the presence of AD- related co- pathologies 
(9– 11). Previous work suggests that APOE haplotype 
also influences the risk of developing hippocampal scle-
rosis (HS) with TDP- 43 proteinopathy in aging (12,13), as 
well as FTD in patients with ALS (14,15). Whether cog-
nitive impairment in ALS patients is related to underly-
ing FTLD or because of another concomitant pathology 
remains unclear.
The purpose of this study was to evaluate the influ-
ence of demographic, genetic, and pathologic features, 
including the presence of concomitant pathologies, on 
cognitive impairment in a neuropathologically defined 
cohort of ALS- TDP patients.
2 |  M ETHODS
2.1 | Standard protocol approvals, 
registrations, and patient consents
All cases meeting criteria for a primary clinicopatho-
logical diagnosis of ALS associated with TDP- 43 pro-
teinopathy were selected from the Neurological Tissue 
Bank (NTB), Hospital Clínic - IDIBAPS Biobank in 
Barcelona from the period 1994 to 2018. In order to 
get a homogeneous sample, patients without TDP- 43 
pathology and mimics were excluded. The study was 
approved by the Ethics Committee of Hospital Clínic 
de Barcelona. All individuals or relatives had given 
their informed consent for the use of brain tissue for 
research.
Salud Carlos III, Spain. This study was 
partially funded by Fundació Marató de 
TV3 (grant no. 20141610 to EG and no. 
20143710 to RRG) and Fondo Europeo de 
Desarrollo Regional (FEDER) (PI15/01618 
to RRG). AA is funded by Departament de 
Salut de la Generalitat de Catalunya, Pla 
estratègic de recerca i innovació en salut 
(PERIS) 2016– 2020 (SLT002/16/00329). 
JG is recipient of the Instituto de Salud 
Carlos III- FEDER grants (PI16/01673 and 
PI19/00593)
(FTLD) were found in 32.7%, explaining most, but not all, cases with cogni-
tive impairment. Extent of TDP- 43 pathology and the presence of hippocam-
pal sclerosis were associated with cognitive impairment. Mutation carriers 
presented a higher burden of TDP- 43 pathology and FTLD more frequently 
than sporadic cases. Most cases (89.4%) presented some degree of concomi-
tant pathologies. The presence of concomitant pathologies was associated with 
older age at death. FTLD, but also Alzheimer’s disease, were the predominant 
underlying pathologies explaining the cognitive impairment in ALS patients. 
In sum, FTLD explained the presence of cognitive decline in most but not all 
ALS cases, while other non- FTLD related findings can influence the cognitive 
status, particularly in older age groups.
K E Y W O R D S
Alzheimer’s disease, amyotrophic lateral sclerosis, ALS- FTD, frontotemporal dementia, 
neuropathology, TDP- 43 protein
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2.2 | Clinical classification
We retrospectively reviewed the medical records avail-
able at the NTB and contacted the neurologists who 
attended the patients during life. As we included ALS do-
nors since 1994, some cases had not been systematically 
screened for cognitive impairment. In those subjects, the 
presence and the grade of cognitive impairment were as-
sessed by the global impression of the treating neurolo-
gist. They were asked to fill in a form that included the 
following clinical information: age at onset, age at death, 
disease duration, site of onset (bulbar/spinal), presence 
or absence of cognitive or behavioral impairment, and 
diagnosis of bvFTD or PPA. The severity of the cogni-
tive/behavioral impairment was retrospectively assessed 
according the CDR® Dementia Staging Instrument plus 
National Alzheimer’s Coordinating Center Behaviour 
and Language Domains (CDR plus NACC- FTLD) (16). 
This rating scale classifies the severity of the dementia 
according eight domains in: no cognitive impairment 
(score of 0), mild cognitive impairment (score of 0.5) or 
mild, moderate or severe dementia (scores of 1, 2, and 
3, respectively). The cognitive domains affected were as-
signed according to the expert opinion of the attending 
neurologist or the neuropsychological evaluation. For 
every patient, we considered the last information avail-
able before death. Cases with insufficient clinical infor-
mation to be classified were excluded from the study. 
With this information, patients were classified into 
three clinical subtypes: i) ALS cognitively not impaired 
(ALSni) when cognitive decline was not present or re-
ported, ii) ALS with cognitive impairment (ALSci) when 
cognitive or behavioral decline were reported but with-
out fulfilling bvFTD or PPA criteria and iii) ALS with 
frontotemporal dementia (ALS- FTD) when patients ful-
filled criteria for bvFTD or PPA (2,17,18).
2.3 | Neuropathological work- up
Neuropathological examination was performed accord-
ing to standardized protocols at the NTB. Half brain 
was dissected in the fresh state, frozen and stored at 
−80°C and the other half was fixed in formaldehyde so-
lution for 3 weeks. At least 25 representative brain areas 
were embedded in paraffin, cut at 5 µm and stained with 
hematoxylin & eosin and luxol fast blue in selected brain 
areas. Immunohistochemistry was performed using var-
ious antibodies including anti- βA4, anti- pTau, anti- RD3 
and anti- RD4 Tau, anti- α- synuclein, anti- ubiquitin, 
anti- p62, anti α- internexin, anti- FUS, and anti- TDP- 43, 
and phTDP- 43. Immunoreaction was visualized by 
the EnVision  +  system peroxidase procedure (DAKO). 
Details on tissue section pretreatment, antibody dilu-
tion, and incubation time are shown in Table S1.
Disease assessment was performed according to in-
ternational consensus criteria. All cases were staged 
following the criteria proposed by Brettschneider for 
ALS (19). Presence of FTLD was established when neu-
ronal loss and gliosis were observed in temporal and/or 
frontal regions (20). FTLD- TDP subtype classification 
was performed based on TDP- 43 or pTDP- 43 immuno-
histochemistry following current recommendations (21). 
HS was considered on HE- stained sections when neuro-
nal loss and gliosis at least in the subiculum and/or CA1 
sector of the hippocampus were observed (22). Cases that 
showed only mild gliosis in subiculum were considered 
incipient HS. In all cases, we evaluated the presence of 
fine TDP- 43 immunoreactive neurites in the CA1 sector. 
As previous reports stated that the presence of TDP- 43 
inclusions in the anterior cingulate may identify patients 
with clinical bvFTD, we specifically assessed this area in 
cases with available tissue (23).
For the analysis of concomitant pathologies, we 
considered the following findings: neurofibrillary 
pathology, staged according to Braak criteria (24), 
β - amyloid phases, evaluated according to Thal criteria 
(25), and neuritic plaque score, assessed according to 
the Consortium to Establish a Registry for Alzheimer 
Disease criteria (26). The National Institute on Aging- 
Alzheimer’s Association (NIAA) Guidelines for neuro-
pathologic assessment of AD were applied and a final 
ABC score was assigned (27). Cerebral amyloid angiop-
athy was recorded as present or absent. Additionally, 
possible and definite PART pathology was defined fol-
lowing the current pathological criteria (28). In order to 
assess whether progressive spinal cord degeneration is 
associated to astroglial tau pathology, we also evaluated 
the presence of age- related tau astrogliopathy (ARTAG) 
at the cervical, dorsal, and lumbosacral spinal level when 
available and defined thorn- shaped astrocytes and gran-
ular fuzzy astrocytes as present/absent, and recorded 
their location (subependymal, subpial, and perivascular) 
and the affected level (cervical, dorsal, and/or lumbo-
sacral) (29). Assignments of Lewy body pathology were 
performed following McKeith criteria (30). Argyrophilic 
grain disease (AGD) was staged according to the Saito 
criteria (31). Limbic- predominant age- related TDP- 43 
encephalopathy (LATE) was evaluated according to the 
recently described criteria, but only in those subjects 
without FTLD, as both are TDP- 43 proteinopathies and 
may overlap in temporomedial regions (32). In addition, 
the presence of granulovacuolar degeneration (GVD) 
was assessed on HE- and ubiquitin- stained sections in 
the hippocampus and, if present, was extended to fur-
ther limbic areas and staged according to Thal et al. (33). 
Vascular pathology including microvascular lesions and 
territorial infarcts were recorded as present or absent.
2.4 | Genetic analysis
DNA was extracted from fresh- frozen cerebellum using 
the QIAamp DNA Mini kit for DNA purification from 
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tissues (QIAGEN Co.) following the manufacturer’s in-
structions. For APOE genotyping two single nucleotide 
polymorphisms (SNPs) in APOE gene were determined 
(rs429358 and rs7412) using TaqMan genotyping technol-
ogies (Life technologies, Carlsbad, USA).
Systematic screening for potential C9orf72 expansion 
mutation carriers was performed searching for ubiqui-
tin/p62- positive inclusions in the cerebellum and hip-
pocampus as surrogate and as reported previously (34). 
The C9orf72 repeat was confirmed in suspected cases by 
repeat- primed PCR and fragment- length analysis (35). 
The identification of other mutations was not performed 
by systematic screening but by previous studies or usual 
clinical practice according to the criteria of the treating 
neurologist (36). Information on other affected family 
members was not available.
2.5 | Statistical analysis
We compared clinical, genetic, and pathology vari-
ables between ALS, ALSci, and ALS- FTD groups with 
χ 2 or Fisher tests for categorical data and Wilcoxon or 
Kruskal– Wallis test for ordinal and continuous data. 
The association of the clinical, demographic, and genetic 
data with the neuropathological findings was assessed 
by Kruskal– Wallis test and Fisher test. Finally, we per-
formed a logistic multivariate regression to test the asso-
ciation between cognitive status and neuropathological 
variables. In this logistic multivariate regression, we 
included the presence of cognitive decline as dependent 
variable and the presence of the following neuropatho-
logical items as independent variables: frontotemporal 
lobar degeneration, hippocampal sclerosis, Alzheimer’s 
disease, Lewy body disease, CAA, PART, ARTAG, 
AGD, GVD, LATE, and vascular pathology. As some 
of these covariates may suffer from relevant collinearity, 
other reduced models including less covariates were also 
assessed. Statistical significance was set at p < 0.05 for 
all analyses.
3 |  RESU LTS
3.1 | Demographic and genetic features of the 
ALS cohort
Of the 112 donors with a neuropathological diagnosis 
of ALS, four were excluded because of the absence of 
TDP- 43 pathology (three ALS- FUS cases and one sub-
ject without pathological inclusions). Another four cases 
were excluded because of incomplete neuropathological 
exam or insufficient clinical information. Finally, a total 
of 104 cases (50 male and 54 female) were included in the 
study. The onset was bulbar in 30.9% of cases. Mean age 
at onset of motor symptoms was 63.8 years (range 29– 87) 
and the mean age at death was 67.7 (range 34– 92).
Cognitive decline was recorded in 40 subjects (38.5%). 
Thirty- one of them (29.8%) fulfilled diagnostic cri-
teria for bvFTD or PPA (29 and 2 cases, respectively), 
while nine were classified as ALSci. Table 1 shows de-
mographic, neuropathological, and genetic features of 
ALSni, ALSci, and ALS- FTD patients. No demographic 
differences in age at onset, age at death or disease du-
ration were found between ALS, ALSci, and ALS- FTD 
patients. Bulbar onset was more frequent in subjects with 
ALS- FTD (p = 0.03).
Most patients (67.6%) were homozygous for APOE 
ε3/ε3, 5.1% had ε2/ε3, 22.2% ε3/ε4, and 5.1% ε4/ε4. None 
of them were homozygous for APOE ε2. No significant 
differences in APOE genotypes were found between 
groups. Mutations in genes reported as causative of or 
at risk for ALS were found in 21 subjects: 14 C9orf72, 
2 TARDBP (p.A90V and p.I383V), 2 SQSTM1 (both 
c.1157C > T), 1 TBK1 (p.T79del), 1 VCP (p.I27V), and 1 
TAF15 (p.G462S). Most of these mutation carriers have 
been previously reported (34,36,37). More than half of 
ALS- FTD subjects presented an ALS/FTD related mu-
tation (61.3%), this percentage was higher than in ALSci 
(0%) and ALSni (3.1%) subjects (p < 0.001).
3.2 | Neuropathological 
features and their relationship with cognitive 
impairment and genetics
Figure 1 summarizes the main neuropathological fea-
tures of ALS patients.
3.2.1 | Brettschneider staging (Figure 2A)
The distribution of the TDP- 43 pathology according to 
the Brettschneider score for ALS was as follows: 9 subjects 
were scored as stage 1, 17 as stage 2, 26 as stage 3, and 51 
as stage 4. In one subject the Brettschneider staging was 
not at all applicable because of the presence of TDP- 43 
pathology in motor cortex and entorhinal region but not 
in inferior olive, medullary reticular formation, prefrontal 
cortex or striatum. The Brettschneider stage was strongly 
associated with the CDR plus NACC FTLD stage of de-
mentia (p < 0.01, Figure 2A). ALS- FTD patients showed 
significant higher Brettschneider stages than ALSni pa-
tients (p < 0.001; see Table 1). The presence of a genetic mu-
tation was associated with a higher Brettschneider stage 
(p < 0.01, Figure 2A), while APOE was not. No significant 
differences concerning disease duration were found be-
tween the different Brettschneider stages.
3.2.2 | Hippocampal sclerosis (Figure 2B)
HS was detected in 10 subjects (9.6%). Other eleven cases 
showed signs of incipient HS. Subjects with ALS- FTD or 
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ALSci presented HS more frequently than ALSni cases 
(p < 0.01 and p < 0.05, respectively). The presence of HS 
was also significantly associated with higher stages in 
the CDR plus NACC FTLD (p < 0.01). HS was strongly 
correlated with Brettschneider staging and presence 
of FTLD: all subjects with HS presented a stage 4 of 
Brettschneider, and 88.2% presented also with FTLD. 
TDP- 43- positive neurites in CA1 sector were not de-
tected in any of the cases with HS or incipient HS in the 
ALSni group. In contrast, two cases with additional AD- 
type pathology showed frequent fine TDP- 43- positive 
neurites in CA1 sector. The presence of a genetic muta-
tion or the APOE ε4 were not associated with a higher 
prevalence of HS.
3.2.3 | Frontotemporal lobar degeneration 
(Figure 2C)
Neuropathological features consistent with FTLD were 
found in 34 subjects (32.7%). Three cases were classi-
fied as type A, 25 as type B, 5 showed mixed features 
of type A and B, and 1 subject had FTLD type C. Most 
cases with neuropathological FTLD fulfilled clinical 
criteria of ALS- FTD (77.1%) or ALSci (14.3%). FTLD 
was strongly associated with higher stages in the CDR 
plus NACC FTLD (p < 0.001). It was present in 87.1% 
of the ALS- FTD cases, in 44.0% of ALSci, and only in 
4.7% of ALSni cases. Moreover, FTLD was present in 
63.0% cases with a Brettschneider ALS stage 4 and in 
TA B L E  1  Demographic, neuropathologic, and genetic features in patients ALS, ALSci, and ALS- FTD
ALSni ALSci ALS- FTD
p valuen = 64 (61.5%) n = 9 (8.7%) n = 31 (29.8%)
Demographic features
Male/female 30/34 4/5 16/15 ns
Age at onset 63.0 (14.3) 67.1 (10.9) 64.3 (11.6) ns
Mean (SD)
Age at death 66.6 (13.6) 71.2 (10.3) 68.7 (10.7) ns
Mean (SD)
Bulbar onset (%) 23.0% 22.2% 54.2% <0.05*
CDR plus NACC FTLD 64/0/0/0/0 0/9/0/0/0 0/0/6/9/16 <0.001
0/0.5/1/2/3
Neuropathologic features
Brettschneider stage (stage 1/2/3/4) 8/15/21/19 0/1/3/5 1/1/2/27 <0.001*
FTLD (%) 4.7% 44.4% 87.1% <0.001*,**,***
HS (%) 6.2% 33.3% 41.9% <0.001*, <0.05**
Genetics
APOE genotype (%)
ε2/ε3 6.3% 0 % 3.7% ns
ε3/ε3 69.8% 55.6% 66.7%
ε3/ε4 20.6% 22.2% 25.9%
ε4/ε4 3.2% 22.2% 3.7%
Mutations (%)
C9orf72 2 (3.1%) 0 (0%) 12 (38.7%) <0.001*,***
TARDBP 0 (0%) 0 (0%) 2 (6.5%)
VCP 0 (0%) 0 (0%) 2 (6.5%)
TBK1 0 (0%) 0 (0%) 1 (3.2%)
SQSTM1 0 (0%) 0 (0%) 1 (3.2%)
TAF15 0 (0%) 0 (0%) 1 (3.2%)
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSci, amyotrophic lateral sclerosis with cognitive impairment; ALS- FTD, amyotrophic lateral sclerosis with 
frontotemporal dementia; CDR plus NACC FTLD, Clinical Dementia Rating Dementia Staging Instrument PLUS National Alzheimer’s Disease Coordinating 
Center frontotemporal lobar degeneration Behaviour and Language Domains; FTLD, frontotemporal lobar degeneration; HS, Hippocampal Sclerosis; ns, 
statistically not significant.
*Significant differences between ALSni and ALS- FTD. 
**Significant differences between ALSni and ALSci. 
***Significant difference between ALSci and ALS- FTD. 
6 of 14 |   BORREGO- ÉCIJA Et Al.
4.3% of cases in stage 3, while it was absent in stages 1 
and 2.
ALS subjects with any genetic mutation presented sig-
nificantly more risk to develop FTLD than ALS without 
known mutations (80.9% vs. 20.4%, OR 15.92, IC 95% 
4.45– 73.66, p < 0.001). By contrast, APOE ε4 was not as-
sociated with a higher risk of FTLD or a specific FTLD 
subtype. Cases carrying the C9orf72 expansion were neu-
ropathologically classified as subtype B or A/B. We did 
not find statistically significant differences in the neuro-
pathological subtypes according the APOE genotype.
3.2.4 | Cingulate involvement (Table 2)
Cingulate involvement was present in 70.0% of cases 
(sparse 16.7%, mild 18.9%, moderate 25.5%, and severe 
grade in 8.9%). All subjects with FTLD showed, at least, 
a mild grade of TDP- 43 pathology in the anterior cin-
gulate. In contrast, 70% of subjects without FTLD pre-
sented none or only sparse pathology in this area.
3.3 | Concomitant pathology
Figure 3 shows some of the representative concomitant 
pathologies found in ALS patients. Figure 4 shows the 
proportion of these concomitant pathologies found in 
our series.
3.3.1 | Presence of concomitant 
neurodegenerative pathologies (Figure 4A)
Considering all concomitant pathologies together, 
most (89.4%) ALS patients presented at least one 
co- pathology at neuropathological examination. 
Concomitant AD neuropathologic changes, accord-
ing to “ABC” score, were found in 52 subjects (50.0%) 
at low, in 8 (7.7%) at intermediate, and in 7 patients 
(6.7%) at high level. CAA was found in 17 cases (16.3%). 
Nearly half (48.1%) of the subjects fulfilled criteria for 
PART pathology (25.0% possible, 23.1% definite). In 
addition, 38.5% presented ARTAG (18.3% granular 
F I G U R E  1  Characteristic neuropathological features of ALS. (A) Cross section through the thoracic spinal cord shows prominent 
degeneration of the lateral and anterior corticospinal tract and atrophy of the anterior horns (higher magnification in E). There is also myelin 
pallor in anterior roots compared to posterior roots. The degeneration of the lateral corticospinal tract is characterized by loss of myelin 
sheaths (B), reduction of axonal profiles (C), and increased macrophagic activity (D), as compared with posterior horns (b, c, d). (F) some 
residual motor neurons (here from the n. XII) may contain granular eosinophilic cytoplasmic inclusions or Bunina bodies (arrow and inset). 
Others may appear as pale spherical inclusions (G). Axonal damage with swellings (H) in anterior horns is well depicted by anti- neurofilament 
immunohistochemistry (large brown structures). I– L: Immunohistochemistry for pTDP- 43 reveals a spectrum of inclusions including a fine 
granular pattern in large motor neurons (I), fibrillar and skein like inclusions (J), compact spherical neuronal inclusions (K), and coiled- 
body like inclusions in oligodendrocytes (L). Scale bars: 20 µm in Bb, Cc, Dd, F; 10 µm in G– L, 100 µm in E
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fuzzy astrocytes, 13.5% thorn- shaped astrocytes, 6.7% 
both), with 8.3% presenting astroglial pathology also 
in the spinal cord. ARTAG pathology was found more 
frequently, but not exclusively, in subjects with AD pa-
thology (44.8% vs. 27.0%, p  <  0.05). GVD was found 
in 42.3% of the subjects and was mostly very mild and 
restricted to the hippocampal subfields CA2/CA1 with 
only mild entorhinal involvement. GVD was not only 
strongly related to AD pathology (p < 0.001), but also 
to the presence of FTLD and the C9orf72 expansion 
(p < 0.05). AGD was detected in 14 subjects (13.5%; 11 
subjects at Saito stage 1, 1 subject at stage 2, and 2 sub-
jects at stage 3), while Lewy body pathology was iden-
tified in 9.6% (seven subjects restricted to brainstem 
nuclei, three with limbic involvement, and only one 
with neocortical involvement). Vascular lesions were 
identified in 14 subjects (13.5%); 11 of them with small 
vessel pathology and only 3 of them presenting large 
vessel infarcts. We observed LATE in 19 (27.1%) of the 
70 ALS cases without FTLD.
3.3.2 | Relationship of concomitant 
pathologies and age at death (Figure 4B)
Concomitant pathologies were more frequent in subjects 
who died at older age. ABC score for AD was signifi-
cantly higher in subjects with older age at death (p < 0.01). 
Particularly, Braak and Braak stages for neurofibrillary 
pathology and amyloid Thal phases were significantly 
increased in older subjects (p  <  0.01). The presence of 
LATE, ARTAG, Lewy body pathology, GVD, and vas-
cular lesions also was significantly higher in older age 
groups (p < 0.05). CAA, PART, and AGD concomitant 
pathologies did not show significant association with age 
at death.
F I G U R E  2  Barplots representing the proportion of ALS cases with (A) the different Brettschneider stage, (B) the presence of hippocampal 
sclerosis and (C) Frontotemporal Lobar degeneration according to their clinical diagnosis, CDR plus NACC FTLD stage, presence of APOE 
ε4, or presence of mutations in genes reported as causative of or at risk for ALS/FTLD
TA B L E  2  Prevalence of TDP- 43 pathology in anterior cingulate 
cortex in ALS spectrum
Presence of TDP- 43 in 
anterior cingulate n (%)
ALSni ALSci ALS- FTD
n = 58 n = 6 n = 26
No 25 (43.1%) 1 (16.7%) 1 (3.8%)
Sparse 14 (24.1%) 1 (16.7%) 0 (0%)
Mild 13 (22.4%) 0 (0%) 4 (15.4%)
Moderate 6 (10.3%) 4 (66.7%) 13 (50%)
Frequent 0 (0%) 0 (0%) 8 (30.8%)
Note: n = 90 cases out of 102.
Abbreviations: ALSci, amyotrophic lateral sclerosis with cognitive 
impairment; ALS- FTD, amyotrophic lateral sclerosis with frontotemporal 
dementia; ALSni, amyotrophic lateral sclerosis without cognitive impairment.
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3.3.3 | Relationship of concomitant 
pathologies with CDR- NACC FTLD (Figure 4C)
Concomitant pathologies were found more frequently 
in subjects with reported cognitive impairment (97.5% 
vs. 84.0%, p < 0.05). The CDR- NACC- FTLD score was 
significantly related to the Braak and Braak stage for 
neurofibrillary pathology (p < 0.01). Subjects with severe 
stages of dementia also presented more GVD pathol-
ogy (p  <  0.05) No significant associations were found 
between the CDR- NACC- FTLD score and Thal phase 
of amyloid, CAA, PART, ARTAG, AGD, Lewy body, 
LATE, or vascular co- pathologies.
3.3.4 | APOE status and concomitant 
pathologies (Figure 4D)
CAA was found more frequently in subjects with an 
APOE ε4 allele (34.6%, vs. 9.6%; p < 0.05). For the rest 
of the concomitant pathologies, no statistical differences 
were according to the APOE status.
F I G U R E  3  Frequent co- pathologies in ALS. (A– C) Segmental hippocampal sclerosis is sometimes better identified in more anterior 
segments of the hippocampus (A, arrowheads). It is characterized by neuronal loss and prominent fibrillar gliosis (B) in the CA1 sector and 
subiculum. In most cases granule cells of the dentate gyrus harbor TDP- 43 protein inclusions in the cytoplasm (C, upper row) and in some 
cases there are abundant fine threads in the CA1 sector within and adjacent to the sclerotic area (C, lower row). (D and E) Argyrophilic grain 
pathology is well depicted by the AT8 anti- tau antibody (D) and consists of grain- like structures along neuronal processes, abundant threads, 
and a diffuse cytoplasmic neuronal staining (pretangle type) instead of compact tangles. They are frequently associated with ballooned neurons 
in the amygdala (E, upper row) and oligodendroglial coiled bodies in temporomedial white matter (E, lower row). Astrocytic tau pathology 
in form of granular fuzzy astrocytes (F, upper row) and thorn- shaped astrocytes in the glia limitans (F, lower row, here as subependymal and 
perivascular thorn- shaped astrocyte) are features of age- related tau astrogliopathy (ARTAG). (G and H) Alzheimer’s disease neuropathologic 
changes have been also found as co- pathology in a fraction of cases. It is characterized by dense cored amyloid plaques with or without amyloid 
angiopathy (G) and tau positive neurofibrillary pathology with tangles, neuropil threads, and dystrophic neurites around amyloid deposits (H). 
(I) Lewy body pathology has been detected less frequently and can be encountered in brainstem neurons (HE, upper row, medulla oblongata) 
and/or limbic system and is well identified with anti- alpha- synuclein antibodies (lower row), where Lewy- neurites are also frequently seen (here 
in the locus coeruleus). Scale bars: 50 µm in B, F, G, H; 20 µm in C (upper and lower panel), D, E, and I (upper and lower panel)
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3.4 | Determinants of cognitive impairment 
in ALS
Finally, to assess whether neuropathologic and concomi-
tant pathologies influence the presence of cognitive im-
pairment in ALS patients a logistic regression analysis 
was performed (Table 3).
Regarding the neuropathological substrate, the 
presence of FTLD was the strongest determinant for 
cognitive decline in our model (OR 359.5, 95% CI 20.4– 
1940.2, p  <  0.001). We also found that the presence 
of AD concomitant pathology independently influ-
enced the development of cognitive impairment in 
ALS patients, especially in those with higher burden 
of pathology (OR 36.5, 95% CI 3.4– 444.2, p  <  0.05). 
Other concomitant pathologies did not influence cog-
nitive symptoms in ALS subjects with these analyses. 
Reduced models considering less covariates in order 
to avoid collinearity problems showed similar results 
(Table S2).
Five subjects with reported cognitive impairment 
(three ALSci and two ALS- FTD) did not present an 
F I G U R E  4  Presence of total 
concomitant pathologies in ALS cases 
(A), distribution of pathology according to 
age at death (B), distribution of pathology 
according to the CDR NACC plus FTLD 
staging (C), and distribution of pathology 
according to the presence of APOE ε4 allele 
(D). Neurofibrillary tangles were staged 
following Braak stages (24). Amyloid 
represents Aβ Thal phases (25). Globally, 
Alzheimer’s disease pathology was staged 
according the NIA/AA guidelines and an 
ABC score was assigned (27). Cerebral 
Amyloid angiopathy (CAA) has been 
reported as absent or present. Vascular 
lesions were classified according to small 
or large vessel pathology. Assignments 
of Lewy Body pathology were performed 
following McKeith criteria (30). Possible 
or definite primary age related tauopathy 
(PART) was assessed according the current 
neuropathological criteria (28). Age- 
related tau astrogliopathy (ARTAG) was 
evaluated according the current criteria 
(29). Argyrophilic grain disease (AGD) was 
staged according to the Saito criteria (31). 
Granulovacuolar degeneration (GVD) was 
staged according to Thal et al (33)
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unequivocal neuropathological substrate explaining their 
symptoms. This situation was found more frequently in 
the ALSci group than in the ALS- FTD group (33.3% vs. 
6.5%; p  <  0.05). The two subjects fulfilling criteria for 
ALS- FTD but lacking an obvious neuropathological 
substrate presented genes reported as pathogenic of or at 
risk for ALS (1 TARDBP and 1 VCP). The TARDBP car-
rier presented frequent TDP- 43 inclusions in amygdala 
with focal gliosis and neuronal loss. The VCP carrier, 
by contrast, had very few TDP- 43 inclusions restricted 
to motor neurons (Brettschneider stage I), but presented 
concomitant AGD pathology (Saito I).
4 |  DISCUSSION
In this work, we have analyzed the potential effects of 
the extent of TDP- 43 pathology, concomitant patholo-
gies, and genetic variables on the cognitive- behavioral 
status in a large series of neuropathologically confirmed 
ALS patients.
Though the growing evidence of ALS and FTLD 
overlap, only few neuropathological series have been 
reported so far (9,38). In our series of neuropathologi-
cally confirmed ALS patients, cognitive impairment was 
reported in more than one- third (38.5%) of cases. Most 
of them showed a pattern of FTLD at neuropathology. 
Neither the Brettschneider stage nor the presence of 
FTLD were associated with sex, age at death or disease 
duration. Spencer et al. recently reported that patients 
with long- duration ALS (>10 years) showed less frequent 
TDP- 43 pathology and less severe lower motor neuron 
involvement. In our series, only six patients had a dis-
ease duration of 10 years or more and two of them had 
no TDP- 43 but FUS pathology (39). However, those 
harboring TDP- 43 pathology had no different TDP- 43 
severity stages (as assessed by Brettschneider staging) 
compared to the standard duration group in their study 
(40). This was also observed in our series. Also in accor-
dance with previous studies, the presence of a mutation 
was the strongest determinant for comorbid ALS and 
FTLD (14), even in the absence of family history within 
the ALS/FTD spectrum (36). Bulbar onset was more fre-
quent in subjects with ALS- FTD, a finding that also has 
been found in other studies (37,41).
We found that an FTLD neuropathological pattern 
and/or HS are the most frequent neuropathologic sub-
strate of cognitive impairment in ALS subjects. Neither 
the Brettschneider stage nor the presence of FTLD or 
HS were associated with disease duration (40). At the 
same time, the presence of cognitive impairment was 
associated with a Brettschneider ALS stage 4 and the 
presence of TDP- 43 pathology in anterior cingulate. In 
such cases, showing extensive ALS and FTLD- related 
TDP- 43 proteinopathy it might be useful either to apply 
both proposed staging systems in parallel, that is, that 
for ALS- TDP and that bvFTD with TDP- 43 inclusions, 
or even to combine both and propose a new staging fus-
ing both particularly when one or the other system fails 
to appropriately classify the pathology. One of the ca-
veats of Brettschneider ALS stages is that the topogra-
phy alone may not explain cognitive symptoms. Previous 
studies have suggested that the burden of TDP- 43 pa-
thology in the anterior cingulate cortex discriminates 
cases with clinical bvFTD (23). In our work, almost all 
subjects diagnosed as ALS- FTD showed at least mild 
TDP- 43 pathology in the anterior cingulate, and this 
was also present in 32.7% of subjects in the ALSni group. 
This finding suggests that the cingulate burden of TDP- 
43 could be more sensitive than specific to discriminate 
cognitive involvement in ALS patients. However, be-
cause of the retrospective methodology of our study, it is 
difficult to elucidate if subtle cognitive alterations might 
have been underdiagnosed in these subjects, especially in 
the last stages of the disease.
Moreover, in HS the presence of TDP- 43 proteinopa-
thy is a frequent finding, independently of motor neuron 
involvement. In ALS cases with HS, the application of 
TDP- 43- stages according to Brettschneider’s proposal 
might result in stage 4 although hippocampal involve-
ment by TDP- 43 would be more likely related to HS and 
not necessarily to a sequential progression of pathology 
from motor regions. Therefore, the staging systems for 
ALS, FTLD, and HS, when appearing concomitantly, 
should be critically rethought. This also applies to the 
TA B L E  3  Logistic multivariate regression
Neuropathologic features Odds ratio (95% CI) p value*
Age at death 0.9 (0.8– 1.0) 0.177
Sex (female) 2.7 (0.6– 14.5) 0.219
Frontotemporal lobar 
degeneration
359.5 (20.4– 1940.2) <0.001
Hippocampal sclerosis 0.3 (0.1– 5.5) 0.459
Alzheimer’s disease 
neuropathological change
36.5 (3.4– 444.2) <0.05
Cerebral amyloid angiopathy 2.9 (0.4– 20.9) 0.279
α- synuclein 2.3 (0.1– 13.7) 0.559
PART 2.3 (0.4– 7.1) 0.325
ARTAG 1.9 (0.4– 6.5) 0.461
Argyrophilic grain disease 1.0 (0.1– 5.5) 0.995
LATE 3.4 (0.3– 11.3) 0.315
Granulovacuolar degeneration 1.7 (0.3– 8.0) 0.542
Vascular lesions 1.5 (0.1– 7.7) 0.748
Note: The dependent (outcome) variable of the model was the presence of 
cognitive impairment (ALSci and ALS- FTD were considered together). 
Frontotemporal lobar degeneration was established according to the presence 
of neuronal loss and gliosis in temporal and/or frontal cortices. Alzheimer’s 
disease neuropathological change was considered as a moderate or high 
burden of tau and amyloid pathology according the NIA- AA.
Abbreviations: ARTAG, age- related tau astrogliopathy; LATE, limbic- 
predominant age- related TDP- 43 encephalopathy. PART, primary age- related 
tauopathy.
*p values were obtained from Wald’s test, bold indicates statistical 
significance. 
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recently described “LATE,” which by itself may also 
contribute to cognitive decline. It should be considered 
a separated entity from FTLD, as it manifests with a 
different phenotype, it occurs particularly in older age 
groups (the “oldest old,” >85 years) and has a relatively 
restricted neuroanatomical distribution (32). In the con-
text of ALS- TDP, whether the presence of TDP- 43 pa-
thology in the limbic system represents LATE pathology, 
or whether it is a restricted form of FTLD, remains a 
matter of discussion.
Our study also reveals a high frequency of concom-
itant pathologies in ALS patients, however, at different 
severity grades. It is currently well known that the accu-
mulation of brain pathologies is common and that these 
may influence the cognitive state or lower the threshold 
for the development of cognitive decline (7,8). The fre-
quencies of concomitant pathologies found in our series 
are in accordance with those reported in previous works 
(9,38). Most ALS patients presented any grade of tau 
pathology in the form of neurofibrillary tangles: PART 
pathology was found in approximately half of the cases; 
around one- third to one- half also presented amyloid- β 
pathology; and about a 10th presented any grade of α- 
synuclein pathology. Our study also evaluated the pres-
ence of ARTAG pathology in the brain and spinal cord 
of ALS subjects, as it represents the most frequent as-
trocytic tau pathology found in aging brains. We found 
that more than a third cases (38.5%) presented ARTAG 
pathology. In a few subjects, ARTAG pathology was also 
found in the spinal cord, particularly in older age groups. 
Whether the spinal astroglial pathology may be elicited 
by the chronic neurodegenerative process or not remains 
a matter of further studies.
In addition, we found a quite considerable preva-
lence of AGD co- pathology in our series (15.5%). AGD 
is a common sporadic neurodegenerative disease of old 
age but is rarely seen in young subjects. Of note, some of 
the subjects with AGD pathology were relatively young 
(mean age at death 70.9  years, range 58– 84). Previous 
reports point that AGD and TDP- 43 are occasionally 
concurrent in ALS/FTLD cases (42,43). These findings 
may strengthen the hypothesis of the existence of a link 
between TDP- 43 pathology and argyrophilic grains. 
However, the pathogenesis of this potential interaction 
remains unclear.
GVD, a feature observed in cellular stress conditions 
and some neurodegenerative pathologies including AD 
was not a frequent feature and, if present, was mostly 
very mild and restricted to the hippocampal subfields 
CA2/CA1 with only mild entorhinal involvement (33). 
GVD was not only more frequently related to AD pa-
thology, including both, neurofibrillary tangles and am-
yloid plaques, but was also observed more frequently in 
individuals with FTLD pathology or in those carrying 
the C9orf72 expansion. An association between GVD 
and TDP- 43 pathologies has been recently reported. It 
has been suggested to be potentially triggered by TDP- 43 
in the hippocampus and has been linked to a cell death 
mechanism (44,45). GVD could, therefore, represent an 
additional, TDP- 43- related mechanism leading to cog-
nitive impairment in ALS besides its relationship with 
Alzheimer’s disease neuropathological change.
In our series the strongest determinant for the pres-
ence of concomitant pathologies was the age at death: 
while subjects aged 60 or less rarely had co- pathologies, 
those >60 years had at least 1, and those >70 years had 
2 or more co- pathologies. Although it is not possible to 
further elucidate this observation given the absence of 
a matched control group in our study, this frequency of 
co- pathologies seems to appear at relatively early ages in 
ALS cases. Moreover, subjects with reported cognitive 
impairment presented with more severe AD pathology.
The presence of the APOE ε4 allele is a well- known 
risk factor to develop AD. For other dementias, this rela-
tionship is not well established. Chio et al. found that the 
presence of the allele ε2 significantly increased the risk 
of cognitive impairment in ALS patients (14). Other stud-
ies, including two meta- analyses, found a relationship 
between FTLD and the presence of the ε4 allele (15,46). 
These studies were limited, as they were not performed 
in a pathologically confirmed cohort or in ALS patients. 
Recently, Yang et al. found an age- dependent effect of 
APOE ε4 on TDP- 43 and HS, (13) and Wennberg et al. on 
TDP- 43 deposition independently of Aß in AD pathol-
ogy in a large postmortem series (12). In our postmortem 
study, we also analyzed the effect of APOE on ALS and 
cognition, but we did not find statistically significant 
associations between APOE ε4 allele and the presence 
of FTLD, FTLD subtypes or HS. Except for CAA, we 
neither found differences in the presence of concomitant 
pathologies in APOE ε4 carriers. Because of the low fre-
quency of the APOE ε2 allele observed in our series, an 
association with the presence or absence of FTLD can-
not be established.
When evaluating the clinical impact of neuropatho-
logical findings, we found that the presence of FTLD 
is, by large, the predominant underlying pathology that 
better explained the cognitive impairment in ALS pa-
tients. However, our analysis reveals that AD also can 
influence the development of cognitive symptoms in 
these patients. In addition, we found a few cases with re-
ported cognitive decline but without FTLD or enough 
AD pathology to justify cognitive impairment. The two 
subjects with ALS- FTD diagnosis lacking an obvious 
neuropathological substrate for cognitive impairment 
were carriers of mutations in genes reported as patho-
genic of or at risk for ALS (1 TARDBP and 1 VCP). The 
TARDBP mutation carrier showed TDP- 43 inclusions 
in amygdala associated with focal gliosis and neuronal 
loss, while the VCP mutation carrier showed mild argy-
rophilic grain pathology with ballooned neurons. The 
involvement of the amygdala in behavioral disturbances 
is well known (47). Therefore, despite not having a clas-
sical FTLD- pattern, the presence of focal amygdala 
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degeneration could have been sufficient explanation for 
the cognitive impairment. So finally, in three ALS cases 
in which cognitive impairment was reported, we found 
no adequate neuropathological explanation. Given the 
retrospective nature of the study, we cannot draw any 
conclusion concerning this finding. However, it may be 
an interesting focus of interest in future studies with pre-
cisely phenotyped series.
Our study has several limitations. First, due the ret-
rospective nature of the study, which included cases 
that had been evaluated years before the acceptance of 
the concept of the ALS- FTLD continuum, two- thirds 
of the subjects had not been systematically screened 
with a formal neuropsychological evaluation, cognition 
was assessed by the global impression of their neurol-
ogist. While this might underestimate the presence of 
cognitive impairment particularly when it was subtle or 
in the last stages of the motor neuron disease, we still 
found a good association between the cognitive infor-
mation reported by the neurologist and the neuropatho-
logical examination. In that sense, further prospective 
studies with accurate screening tools for cognitive 
decline are needed to validate the conclusions of this 
work. Second, as a single Brain Bank series, it is pos-
sible that our results do not represent the whole ALS 
population. Therefore, some clinical or genetic features 
may be overrepresented because of a selection bias for 
brain donation. Finally, while a morphological screen-
ing for C9orf72 was performed in all cases, genetic tests 
for other mutations have not been performed systemat-
ically (34).
5 |  CONCLUSIONS
Cognitive impairment is a frequent finding in patients 
with ALS. Most, but not all cases, present with FTLD 
with or without hippocampal sclerosis as the underly-
ing pathology, have higher ALS- Brettschneider stages 
and higher burden of TDP- 43 pathology in the anterior 
cingulate. AD can also influence the development of 
cognitive symptoms in ALS patients. The presence of a 
mutation, but not the APOE genotype, is a strong deter-
minant for the presence of cognitive decline. Moreover, 
concomitant neurodegenerative pathologies, particu-
larly AD, are more frequent in older ALS subjects with 
cognitive decline, while AGD may appear earlier than in 
non- ALS patients.
These findings contribute to broaden the knowledge 
on the overlap between ALS and FTD and emphasize 
the importance of an accurate assessment of non- motor 
features in ALS patients including clinical, neuropsycho-
logical, neuroimaging, and biofluid biomarkers through 
an integrative approach. Well- characterized patients 
will undoubtedly profit from better directed therapeutic 
interventions and care.
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